- Johnson & Johnson stock price today and history
Johnson & Johnson (JNJ) stock prices updated...
Please, Signup (Login) to subscribe or trade (demo)
Johnson & Johnson stock price, JNJ
Johnson & Johnson stock chart:
Johnson & Johnson close price: 125.48
Stock price forecast:
DOWN TO -4.34%
Total forecasts: 89
Reached: 51 (57.30%)
Total Win: 85.40 (74.86%)
Showing 1-10 of 512 items.
|Date of Forecast||Stock Price||Target Price||Forecast Reached Date|
Johnson & Johnson latest news:
Stocks close fractionally higher as ECB stands pat on easing
U.S. stocks finished slightly higher Thursday after European Central Bank President Mario Draghi left easing measures in place but downplayed deflation concerns. The Dow Jones Industrial Average advanced 2.46 points to finish at 20,858.19 led higher by shares of Johnson & Johnson Inc. . The S&P 500 index closed up 1.89 points, or just under 0.1%, at 2,364.87, as health-care and energy stocks gained. The Nasdaq Composite index finished up 1.25 points at 5,838.81.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Johnson & Johnson wins trial in talc product liability lawsuits
- Johnson & Johnson said on Friday that a state court jury in Missouri had returned a verdict in its favor in the latest trial to arise out of thousands of lawsuits alleging the company's talc-based products can increase the risk of ovarian cancer.
Stocks of manufacturers whose CEOs are meeting Trump mostly lower, led by US Steel
The stocks of the manufacturing companies which were meeting with President Donald Trump Thursday were trading mostly lower. The drop comes amid reports that an infrastructure spending plan may be delayed until next year, and tax reform pushed back until at least the summer. United States Steel Corp. led the decliners, falling 6.7% in mid-morning trade. Caterpillar Inc. fell 2.4%, and Emerson Electric Co. fell 1.7%. Lockheed Martin Corp. and Corning Inc. were all down 0.7%. GE was down 0.5%, Whirlpool Corp. was down 0.4% and Dow Chemical Co. was down 0.3%. Goldman Sachs Group Inc. shares were trading down 0.7%. Goldman and Caterpillar combined were shaving about 30 points off the Dow Jones Industrial Average . Trump introduced Goldman's ex-COO Gary Cohn, now National Economic Council director, to the group as "Gary from Goldman." The only two stocks to gain were Johnson & Johnson and International Paper Co. , which were both up less than 1%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Johnson & Johnson refills drug cabinet with $30 billion Actelion deal
ALLSCHWIL, Switzerland (Reuters) - U.S. healthcare giant Johnson & Johnson will buy Swiss biotech company Actelion in a $30 billion all-cash deal that includes spinning off Actelion's research and development pipeline, the companies said on Thursday.
Johnson & Johnson agrees $30bn deal for Actelion
Founder Jean-Paul Clozel to head up standalone spin-off research company
Johnson & Johnson to buy Actelion for $30bn
Swiss biotech group’s founder to head up standalone spin-off research company
Johnson & Johnson to Acquire Actelion for $30 Billion
The acquisition of the Swiss biotechnology company will improve Johnson & Johnson’s portfolio of drugs to treat rare diseases.
Johnson & Johnson to buy Actelion for $30 billion, spin off R&D unit
ZURICH (Reuters) - U.S. healthcare giant Johnson & Johnson will acquire Swiss biotech company Actelion in a $30 billion all-cash deal that includes spinning off Actelion's research and development pipeline, the companies said on Thursday.
Johnson & Johnson Opens 2017 on a Cautious Note
The healthcare conglomerate forecast lower revenue and earnings growth than investors had hoped.
J&J, Actelion approach Swiss takeover board over deal structure: paper
ZURICH (Reuters) - Johnson & Johnson and Actelion have asked Switzerland's takeover board about the viability of a complicated takeover deal the U.S. healthcare company is discussing with the Swiss biotech firm, newspaper Tages-Anzeiger reported on Friday, without saying how it got the information.
Exclusive: J&J discussing breaking up Actelion in an acquisition - sources
(Reuters) - Johnson & Johnson is negotiating a deal to acquire Swiss biotechnology company Actelion Ltd that would separate its commercialized portfolio from its research and development (R&D) assets, people familiar with the matter said on Thursday.
Jones Lang LaSalle IncorporatedJLL
Journal Media GroupJMG
Joy Global Inc.JOY
JP Energy Partners LPJPEP
JPMorgan China Region FundJFC
Jumei International Holding LimitedJMEI
Jupai Holdings LimitedJP